Date of Document: September 15, 2026

# CURRICULUM VITAE

## Ehab L. Atallah MD

**Professor**
**Department of Medicine**
**Division of Medicine Hematology Oncology**


**OFFICE ADDRESS:**

8800 W. Doyne Avenue

Milwaukee, WI 53226
Phone: +1 (414) 8054600
Email: eatallah@mcw.edu


**EDUCATION:**

12/1988 - 12/1994 M.D., School of Medicine, Cairo University, Cairo, Egypt
1988 University of London School Examination Board, Kano, Nigeria

**POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:**

03/1995 - 03/1996 Internship, Cairo University Hospitals, Cairo, Egypt
03/1996 - 03/1999 Resident, Medical Oncology & Radiotherapy, Cairo University, Cairo, Egypt
09/1999 - 06/2000 Assistant Lecturer of Clinical Oncology, Cairo University, Cairo, Egypt
07/2000 - 06/2003 Resident, Internal Medicine, Fairview Hospital, Cleveland Clinic Health System, Cleveland, OH
07/2003 - 06/2005 Fellow, Hematology/Oncology, Karmanos Cancer Institute, Detroit, MI
07/2005 - 06/2006 Chief Fellow, Hematology/Oncology, Karmanos Cancer Institute, Detroit,, MI
07/2006 - 06/2007 Leukemia Fellow, MD Anderson Cancer Center, Houston, TX

**FACULTY APPOINTMENTS:**

07/2007 - 12/18/2010 Staff Physician, Zablocki Veterans Affairs Medical Center, Milwaukee, WI
07/2007 - 07/2014 Assistant Professor of Medicin, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
07/2014 - 07/2019 Associate Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
10/2018 - 10/2023 Hematological malignancies disease-oriented team lead, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
10/2018 - 09/2023 Section Head of Hematological Malignancies, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
01/2019 - Present Professor of Medicine, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

**EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:**

2009 - Present Member, Fellowship committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2009 - 2013 Committee of Intern Selection, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

**HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:**

2008 - Present Staff discussant, Hematologic malignancy tumor board, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2010 - 2022 Member, Oncology PNT Subcommittee, Medicine, Hematology and Oncology, Medical College

of Wisconsin, Milwaukee, WI
2011 - 2012 Member, Antibiotic PNT Subcommittee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2012 Member, Leukemia Business Planning Committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2012 - 2013 Member, Cancer Center Working Group, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2014 - Present Member, Blood Management Committee FMLH, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2022 - Present Associate director of the cancer service line, Medicine, Hematology and Oncology, Froedtert Hospital / Medical College of Wisconsin, Milwaukee, WI

**RESEARCH ADMINISTRATIVE APPOINTMENTS:**
2013 - 2023 Co-chair, MCW Data Safety Monitoring Committee, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2017 Clinical Translational Pilot Grant Committee Member, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2021 American Cancer Society's Institutional Research Grant Review Committee
2021 MCWCC Pilot Grant application, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
2021 GSPMC/CC Joint Pilot Study Section

**HOSPITAL STAFF PRIVILEGES:**
07/2007 - Present Froedtert Memorial Lutheran Hospital, 9200 W Wisconsin Avenue, Milwaukee, WI 53226

**SPECIALTY BOARDS AND CERTIFICATION:**

| Board Certified | Issue Date | Expiration |
|---|---|---|
| Internal Medicine | 08/2003 | 08/2013 |
| Hematology | 08/2006 | 08/2016 |
| Oncology | 08/2006 | 08/2016 |

| Licensure | Number | Issue Date | Expiration |
|---|---|---|---|
| Wisconsin License | 50252-20 | 07/01/2007 | 10/31/2025 |

**AWARDS AND HONORS:**
06/2001 Best First Year Resident, Fairview Hospital, Cleveland, OH
07/2007 Merit award, ASCO Cancer Foundation
03/2009 Dennis M. Bush Excellence in Teaching Award, Division of Hematology and Oncology, Medical College of Wisconsin
06/2009 Teacher of the Year Award by Internal medicine residents, Medical College of Wisconsin
2010 Best Ten Teaching Faculty Award by Internal Medicine Residents, Medical College of Wisconsin
2014 Outstanding Medical Student Teacher Award, Medical College of Wisconsin
2015 Department of Medicine Engstrom Murphy Award for Clinical Contribution, Medical College of Wisconsin
2015 - 2023 The Best Doctors in America, Medical College of Wisconsin
2016 Outstanding Medical Student Teacher Award, Medical College of Wisconsin
2016 Faculty Development Award, Medical College of Wisconsin
2017 MCW Program Mentor Award, Medical College of Wisconsin
2017 Top Scores in Patient Satisfaction, Medical College of Wisconsin
2021 Outstanding Medical Student Teacher Award, Medical College of Wisconsin

**MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:**
2007 - Present American Society of Hematology

**EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:**

Editorship

01/2018 - Present Overview of the treatment of chronic myeloid leukemia; Initial treatment of chronic myeloid leukemia in chronic phase

01/2018 - Present Accelerated phase CML: Diagnosis and treatment; Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy

Editorial Board

2017 - 2021 Leukemia Research

American Cancer Society

Oncology

Journal Review

American Journal of Hematology

Biology of Blood and Marrow Transplantation

Blood Advances

Blood (Journal of the American Society of Hematology)

Hematologica (Journal of the European Hematology Association)

Clinical Lymphoma, Myeloma and Leukemia

Cancer

Leukemia Research: Outstanding reviewer 2015: top 10th percentile in terms of the number of reviews completed for Leukemia Research in the past two years

Annals of Oncology

Clinical Leukemia

**LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

07/2018 Medical College of Wisconsin Faculty Council

**NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

2015 Reviewer: Review research proposals for scientific relevance and merit, ASPIRE Oncology/Hematology Research Awards program, Pfizer ASPIRE Grants

11/2017 - Present Toxicity Monitor, Eastern Cooperative Oncology Group (ECOG)

2017 - Present Administrative director, H. Jean Khoury Cure CML Consortium

2017 Reviewer: Review research proposals for scientific relevance and merit, ASPIRE Oncology/Hematology Research Awards program, Pfizer ASPIRE Grants

2018 - Present Clinical basket chair for patients < 60 years old with AML, myeloMATCH precision medicine initiative

02/03/2023 - Present Steering Committee Chair, Phase II multi-center, open-label, single arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE)

03/29/2023 - Present Co-Chair, ECOG-ACRIN Leukemia

09/28/2023 - Present The iCMLf Scientific Advisory Board

**RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:**

**Active**

**Peer Review**

| | |
|---|---|
| Title: | RAS pathway activation without acquisition of RAS mutation as a drug resistance mechanism in acute myeloid leukemia |
| Source: | 2023 CTSI Traditional Pilot Award |
| Role & Effort: | Co-I (PI Karen Carlson, MD and, Nan Zhu, PHD) |
| PI: | Ehab Atallah |
| Dates: | 06/01/2023 - 06/01/2024 |
| Title: | A041703- Inotuzumab Ozogamicin & Blinatumomab in Patients w/ Newly |

| | |
|---|---|
| | Diagnosed, Recurrent, or Refractory ALL |
| Source: | NCI-Alliance |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | S1712, “A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCRABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease |
| Source: | ECOG/ACRIN |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Venetoclax and Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell ALL |
| Source: | ECOG/ACRIN |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase 1 Study of HMPL-306 in Advanced Hematological Malignancies with mIDH |
| Source: | Hutchison MediPharma |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

**Prior**

**Peer Review**

| | |
|---|---|
| Title: | Phase IIB, Multicenter, Randomized, open label Trial of CPX-351 (cytarbine:Daunorabicin) Liposome injection versus cytarabine and Daunorubicin in patients with untreated AML 60-75 years of age |
| Source: | Celator Pharm/CLTR0308-204 |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 07/16/2009 - 07/15/2013 |
| Direct Funds: | $7,280 |
| Title: | A Randomized Double-Blind, Placebo-controlled Study of the JAK inhibitor INCB018424 tablets administered orally to Subjects with Primary Myelofibrosis (DMF), post polycythemia vera-Myelofibrosis (PPV0MF) or Post Essential Thrombocythemia |
| Source: | PPD Development/INCB 18424-351 |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 10/29/2009 - 10/28/2012 |
| Direct Funds: | $19,232 |

| | |
|---|---|
| Title: | A Randomized Double-Blind, Placebo-controlled Study of the JAK inhibitor INCB018424 tablets administered orally to Subjects with Primary Myelofibrosis (DMF), post polycythemia vera-Myelofibrosis (PPV0MF) or Post Essential Thrombocythemia |
| Source: | PPD Development/INCB 18424-351 |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 01/27/2010 - 01/26/2013 |
| Direct Funds: | $19,513 |

| | |
|---|---|
| Title: | A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults with Primary Refractory or Initial Relapse of Acute Myelogenous Leukemia (AML) |
| Source: | ECOG |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 09/10/2010 - 2024 |

| | |
|---|---|
| Title: | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ? 60 Years) |
| Source: | ECOG |
| PI: | Ehab Atallah, MD |
| Dates: | 04/21/2011 - 2024 |

| | |
|---|---|
| Title: | A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine |
| Source: | Onconova Therapeutics Inc |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 08/24/2011 - 2024 |

| | |
|---|---|
| Title: | A Phase III Randomized Study of Oral |

| | |
|---|---|
| | Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia |
| Source: | Cyclacel |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 10/13/2011 - 2024 |
| | |
| Title: | A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
| Source: | ECOG |
| PI: | Ehab Atallah, MD |
| Dates: | 08/02/2012 - 2024 |
| | |
| Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia |
| Source: | Gilead sciences |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 2012 - 2024 |
| | |
| Title: | Protocol I3X-MC-JHTC(a) A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients with Myeloproliferative Neoplasms |
| Source: | Lilly |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 05/06/2013 - 2024 |
| | |
| Title: | Phase II two-stage dose finding run-in study of SAR3419, an anti-CD19 antibodymaytansine conjugate, administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) |
| Source: | Sanofi |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Dates: | 06/10/2013 - 2024 |
| | |
| Title: | The Life After Stopping Tyrosine Kinase Inhibitors (The LAST study) |
| Role & Effort: | Co-PI with Kathryn Flynn, PhD |

| | |
|---|---|
| PI: | Ehab Atallah |
| Dates: | 09/19/2014 - 08/31/2021 |
| Title: | Peripheral Blood and Bone Marrow Collection for Optimizing T-cell Adoptive Cell Transfer for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Source: | Advancing a healthier Wisconsin |
| Role & Effort: | Co-I |
| PI: | Ehab Atallah |
| Dates: | 02/01/2017 - 01/31/2019 |
| Title: | A pilot study to investigate the hypomethylating properties of freeze-dried black raspberries (BRBs) in patients with myelodysplastic syndrome |
| Source: | Medical College of Wisconsin (MCW) Cancer Center and Froedtert Hospital Foundation |
| Role & Effort: | PI |
| PI: | Ehab Atallah |
| Dates: | 05/01/2017 - 04/30/2019 |
| Direct Funds: | $149,342 |
| Title: | National chronic myeloid leukemia registry |
| Source: | MCW Cancer Center |
| Role & Effort: | Co-PI (Atallah-Flynn) |
| PI: | Ehab Atallah, MD |
| Dates: | 04/01/2018 - 03/31/2019 |
| Title: | Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) for Underrepresented Minority Students |
| Role & Effort: | Co-Investigator |
| PI: | Janet Rader |
| Dates: | 09/18/2018 - 08/31/2023 |
| Title: | A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) Role in project: Principle investigator |
| Source: | Medical College of Wisconsin Cancer Center |
| Role & Effort: | Principle investigator |
| PI: | Ehab Atallah, MD |
| Title: | HJKC3-0005: H. Jean Khoury Cure CML Consortium (HJKC3) Registry |
| Source: | H Jean Khoury Cure CML Consortium |
| Role & Effort: | National PI (co-PI Kathryn Flynn, PHD) |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | Protocol CA180399: An Open Label, Randomized Phase 2B Study Of Dasatinib Vs. Imatinib In Patients With Chronic Phase Chronic Myeloid leukemia Who Have Not Achieved An Optimal Response To 3 Months Of Therapy With 400 Mg Imatinib |
| Source: | BMS |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia |
| Source: | Gilead sciences |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | Protocol I3X-MC-JHTB(a) A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms |
| Source: | Lilly |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase I, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML), or Patients with CD25-positive AML who are not Candidates for Treatment with Hypermethylating Agents |
| Source: | ADC Therapeutics |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | INCB053914 in Subjects With Advanced Malignancies |
| Source: | Incyte |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase III Open-Label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation |
| Source: | Astellas Pharma Global Development, Inc./APGD |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | Phase III, Multicenter, Randomized, Trial Of CPX-351(cytarabine:daunorubicin) Liposome Injection Versus Cytarabine And Daunorubicin In Patients 60-75 Years Of Age With Untreated High Risk (Secondary) AML |
| Source: | Celator Pharmaceuticals, Inc. |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase II Open-Label, Single-Arm, Two-Stage, Multicenter Trial Of Pracinostat In Combination With Azacitidine In Elderly (age 65 plus Years) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Source: | MEI Pharma |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination with Azacitidine in Patients with Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High-risk Myelodysplastic Syndrome (MDS) |
| Source: | Seattle Genetics |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents |
| Source: | MedImmune, LLC |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | ALLIANCE-A041501- A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell All |
| Source: | ECOG/ACRIN |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and |

| | |
|---|---|
| | Young Adults (AYA) with Acute Leukemia and Minimal Residual Disease |
| Role & Effort: | Study Vice Chair |
| PI: | Ehab Atallah, MD |
| Title: | Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders |
| Source: | ECOG/ACRIN |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML) |
| Source: | Takeda and Abbvie |
| Role & Effort: | Principle Investigator (Co-PI Dr. Guru Subramanian Guru Murthy) |
| PI: | Ehab Atallah, MD |
| Title: | Assessment of allogeneic hematopoietic stem cell transplantation in Medicare Beneficiaries with myelodysplastic syndrome and related disorders |
| Source: | CIBMTR |
| Role & Effort: | PI |
| PI: | Ehab Atallah, MD |
| Title: | HJKC3-0006: Real World Outcome of Patients with CML Treated on Second Line or Later Therapy |
| Source: | H Jean Khoury Cure CML Consortium/Takeda |
| Role & Effort: | PI (co-PI Kathryn Flynn, PhD, James Thompson, MD, Michael Mauro, MD) |
| PI: | Ehab Atallah, MD |
| Title: | A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia |
| Source: | Gilead Sciences |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase III, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab versus Chemotherapy in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) |

| | |
|---|---|
| Source: | Amgen |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Multi-Center, Open-Label, Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Subopotimal Molecular Response to Imatinib |
| Source: | Novartis |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | HKC3-0004: Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase |
| Source: | H Jean Khoury Cure CML Consortium/Novartis |
| Role & Effort: | Institutional PI, steering committee (Jorge Cortes, MD PI) |
| PI: | Ehab Atallah, MD |
| Title: | Clavis_CP4055-306: A Randomised Phase III Study of Elacytarabine vs. Investigator´s Choice in Patients with Late Stage Acute Myeloid Leukaemia |
| Source: | Clavis_CP4055-306 |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | HKC3-0002: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors |
| Source: | H Jean Khoury Cure CML Consortium/Incyte |
| Role & Effort: | Institutional PI and administrative director |
| PI: | Ehab Atallah, MD |
| Title: | KRT-232 and TKI Study in Chronic Myeloid Leukemia |
| Source: | Kartos |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk |
| Source: | AstraZeneca |
| Role & Effort: | Institutional PI |

| | |
|---|---|
| PI: | Ehab Atallah, MD |
| Title: | HJKC3-0007: Real World Outcomes of Patients with CML-CP Treated with Asciminib and Other Tyrosine Kinase Inhibitors (Novartis funded, 5 years) |
| Source: | H Jean Khoury Cure CML Consortium/Takeda |
| Role & Effort: | PI (co-PI Kathryn Flynn, PhD, James Thompson, MD, Michael Mauro, MD) |
| PI: | Ehab Atallah, MD |
| Title: | A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients with IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated with Hypomethylating Agents |
| Source: | MEI Pharma |
| Role & Effort: | National PI |
| PI: | Ehab Atallah, MD |
| Title: | Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) |
| Source: | Novartis |
| Role & Effort: | National PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) |
| Source: | ADC Therapeutics |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in elderly subjects with treatment Refractory or Relapsed Acute Myeloid Leukemia |
| Source: | Quintiles/CHR – 2797-038 |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes |

| | |
|---|---|
| Source: | Incyte |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF) |
| Source: | ECOG/ACRIN |
| PI: | Ehab Atallah, MD |
| Title: | A Phase II Randomized, Multicenter Study Of Treatment-Free Remission In Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Patients Who Achieve And Sustain MR4.5 After Switching To Nilotinib |
| Source: | Novartis |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Phase I of modified VXLD plus MLN9708 in adults with relapsed or refractory acute lymphoblastic leukemia |
| Source: | Research grant from Millenium |
| Role & Effort: | Investigator |
| PI: | Ehab Atallah, MD |
| Title: | A Phase I/II Study of Lintuzumab-Ac225 In Older Patients with Untreated Acute Myeloid Leukemia |
| Source: | Actinium Pharmaceuticals, Inc. |
| PI: | Ehab Atallah, MD |
| Title: | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension) |
| Source: | GSK |

| | |
|---|---|
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase I Clinical Trial of Vorinostat in Combination With Decitabine in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
| Source: | Covance |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia |
| Source: | ECOG/ACRIN |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase 1 study of XmAb18968 (CD3-CD38) for the treatment of patients with relapsed/refractory acute leukemia and T cell lymphoblastic lymphoma |
| Source: | Xencor |
| Role & Effort: | Principle Investigator (Co-PI Dr. Guru Subramanian Guru Murthy) |
| PI: | Ehab Atallah, MD |
| Title: | Incyte-Jak-2-351 A Randomized, Double Blind, Placebo-Controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF) |
| Source: | PPD Development |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Tolero-TOI-ALV-201: A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML |
| Source: | Tolero Pharmaceuticals, Inc |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase III Randomized Trial of |

| | |
|---|---|
| | Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults |
| Source: | ECOG/ACRIN |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Phase I of Standard Maintenance plus MLN9708 Maintenance Therapy in adults with Acute Lymphoblastic Leukemia in Complete Remission |
| Source: | Research grant from Millennium |
| Role & Effort: | PI |
| PI: | Ehab Atallah, MD |
| Title: | A Phase II Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy |
| Source: | Acerta Pharm |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | HKC3-0003: Treatment Free Remission After Combination Therapy With Asciminib Plus Imatinib |
| Source: | H Jean Khoury Cure CML Consortium/Novartis |
| Role & Effort: | National PI and administrative director (Michael Mauro, MD study chair) |
| PI: | Ehab Atallah, MD |
| Title: | Eradicating Measurable Residual disease in patients with AML prior to StEm cell transplantation |
| Source: | ECOG/NCI/Myelomatch |
| Role & Effort: | PI |
| PI: | Ehab Atallah, MD |
| Title: | A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
| Source: | Avillion |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |
| Title: | Open Label Ib/IIa Trial of a Combination of IPH2201 and Ibrutinib in Patients with Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia |
| Source: | Innate Pharma |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

| | |
|---|---|
| Title: | Onconova 09-08: Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib with Azacitidine in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia |
| Source: | Onconova Therapeutics, Inc |
| Role & Effort: | Institutional PI |
| PI: | Ehab Atallah, MD |

**INVITED LECTURES/WORKSHOPS/PRESENTATIONS:**

**International**

Ehab Atallah, MD, 5th International Congress on Leukemia Lymphoma Myeloma, Turkish Society of Hematology 2015, CML: Molecular Monitoring and Treatment-free Remissions, Istanbul, Turkey, 05/21/2015 - 05/23/2015

Ehab Atallah, MD, 24th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, The LAST Trial: The Value of PRO After Treatment Discontinuation, Mandelieu- La Napoule, France, 10/21/2022 - 10/23/2022

Ehab Atallah, MD, Biology and Therapy, 25th Annual John Goldman Conference on Chronic Myeloid Leukemia, Mandelieu- La Napoule, France, 10/06/2023 - 10/08/2023

**National**

Ehab Atallah, MD, Leukemia: Have We Made Progress?, Grand rounds: Chicago Medical School at Rosalind Franklin, Chicago, IL, 09/23/2009

Ehab Atallah, MD, Cincinnati VA Medical Center grand rounds, Cincinnati, OH, 3/24/2010 Aleda E Lutz VA Medical Center grand rounds, Saginaw, MI, 4/30/2010 VA Western NY Medical Center grand rounds, Buffalo, NY, 5/12/2010 VA Pittsburgh Healthcare System grand rounds, Pittsburgh, PA, 5/18/2010 Louis A Johnston VA grand rounds, Clarksburg, WV, 7/7/2010, CML, CME lecture series, 2010 - 2012

Ehab Atallah, MD, Myeloproliferative neoplasms, Grand rounds: Chicago Medical School at Rosalind Franklin, Chicago, IL, 06/01/2011

Ehab Atallah, MD, New Advances in Oncology AML: The case for 7 +3, Update in Chronic Lymphocytic Leukemia, Marquette General Hospital, MI, 05/04/2012

Ehab Atallah, MD, COMFORT-I Publication Steering Committee, 08/18/2012

Ehab Atallah, MD, Myelodysplastic syndrome: Have we made any progress, Advances in Hematology and oncology-Green Bay symposium, 10/06/2012

Ehab Atallah, MD, The Confusing Treatment Landscape in CML: A Welcome Development, Northwestern University's Grand Rounds Lecture Series, 04/04/2014

Ehab Atallah, MD, Acute Promyelocytic Leukemia, The 42nd Annual Dameshek Symposium, Wichita, Kansas, 05/16/2014

Ehab Atallah, MD, Chair of the Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant (Oral Abstract Session), 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, 06/06/2016

Ehab Atallah, MD, Collaborative Approaches to the Treatment of CML, CME lecture series, Inova Alexandria Hospital, 2/24/16 The George Washington University Hospital, 4/29/16 LSU Health Sciences Center - Feist Weiller Cancer Center, 5/20/16 Rush University Medical Center, 6/1/16, 2016

Ehab Atallah, MD, Chair Educational Session: Chronic Myeloid Leukemia: What Every Practitioner Needs to Know, ASCO 2017, 06/03/2017

Ehab Atallah, MD, Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Is It Ready for Prime Time?, ASCO 2017, 06/03/2017

Ehab Atallah, MD, CML Monitoring and TKI Discontinuation, Charles L. Spurr Piedmont Oncology Symposium, Wake Forest School of Medicine, 09/16/2017

Ehab Atallah, MD, Chair Treatment of CML session: 10th International Congress. Myeloproliferative neoplasms and Chronic Myeloid Leukemia, Diagnosis, Management and new clinical developments,

New York, NY, 10/03/2017

Ehab Atallah, MD, 10th International Congress. Myeloproliferative neoplasms and Chronic Myeloid Leukemia, Diagnosis, Management and new clinical developments. Generic Imatinib vs. second generation TKIs, New York, NY, 10/03/2017

Ehab Atallah, MD, ASH Review: Current Updates in Hematologic Diseases, CML-An update, University of Kansas, 02/10/2018

Ehab Atallah, MD, Chair of the Hematologic Malignancies-Leukemia, Myelodysplastic Syndromes, and Allotransplant, American Society of Clinical Oncology (ASCO) Annual Meeting, 06/02/2018

Ehab Atallah, MD, 20th Annual John Goldman Conference on Chronic Myeloid Leukemia, European Society of Hematology, Miami, FL, 09/13/2018 - 09/16/2018

Ehab Atallah, MD, OncLive® State of the Science Summit: Hematologic Malignancies, CML-Treatment Free Remission, 09/13/2018

Ehab Atallah, MD, Subject Matter Expert, ASCO Advantage, 01/03/2019

Ehab Atallah, MD, Can we improve CML outcome?, Houston Methodist Oncology Grand Rounds, 04/02/2019

Ehab Atallah, MD, Focus on Leukemias, Lymphomas, and Myeloma Treatment Discontinuation in CML: Dos and Don'ts, 24th Annual International Congress on Hematologic Malignancies®, Miami, FL, 03/01/2020

Ehab Atallah, MD, Debate: What is the Main Objective of Therapy in CML? Treatment Free Remission; Who May Benefit From A 2nd Generation TKI In First Line Management Of Chronic Phase CML?, Virtual Great Debates & Updates in Hematologic Malignancies, 08/29/2020

Ehab Atallah, MD, Current research in CML and the impact of COVID-19, iCMLf webinar, 09/22/2020

Ehab Atallah, MD, SOHO Session Chair: General Session VI CML, 09/09/2021

Ehab Atallah, MD, Chair of the Translating New Updates on Efficacy of TKIs into Chronic Myelogenous Leukemia (CML) Therapy Practice | Satellite Symposium, 8th Annual Congress of The European Society for Translational Medicine, 09/23/2021

Ehab Atallah, MD, Special education session on collaborative Hematology Networks, ASH, The H. Jean Khoury Cure CML Consortium, 2021

Ehab Atallah, MD, Spotlight on CML, Leukemia, Lymphoma Society, 09/28/2022

Ehab Atallah, MD, The New + Emerging Treatments: CML, Leukemia Research Foundation, 10/12/2022

Ehab Atallah, MD, Update on Management of CML: New Agents and Monitoring for MRD, Lymphoma, Leukemia and Myeloma, New York, New York, 10/19/2022

Ehab Atallah, MD, Leukemia, Lymphoma Society: Upper Midwest Blood Cancer Conference, Minneapolis, MN, 11/05/2022

Ehab Atallah, MD, ASH/FDA Joint Symposium on Late Breaking Drug Approvals, 64th ASH Annual Meeting and Exposition, 12/2022

Ehab Atallah, MD, iCMLf Key Discussions in CML: The realities of Treatment Free Remission in Low and Middle Income Countries, 04/2023

Ehab Atallah, MD, Chronic Myeloid Leukemia: Clinical and Epidemiological: Novel Therapeutic Approaches, Ash 2023, 12/11/2023

Ehab Atallah, MD, Are we curing Leukemia yet?, Grand Rounds Fairview Hospital, Cleveland OH, 12/2027

**Regional**

Ehab Atallah, MD, AML, CME lecture, Fond du Lac Cancer center, 01/29/2013

Ehab Atallah, MD, CML, CME program, Elmbrook Hospital, 05/21/2013

Ehab Atallah, MD, Inaugural Leukemia Survivorship conference, Oshkosh, WI, 02/21/2015

Ehab Atallah, MD, Conversations with Scientists: Cancer- Past, Present and Future, Advancing a Healthier Wisconsin program, 05/11/2016

AA & MDSIF Bone Marrow Failure Disease Symposium, WI, 11/04/2016

Ehab Atallah, MD, -CML: 9/24/16 -CML: 9/23/17 -CML: 9/22/18 -CLL Emerging Therapies: 9/21/19 -CML: 10/16/20, Leukemia, Lymphoma Society Blood Cancer Conference, WI, 2016 - 2020

Ehab Atallah, MD, Understanding the CTO protocol development process, Investigator initiated trials. Boot Camp series, 02/17/2017

Ehab Atallah, MD, How can we improve CML therapy?, grand rounds, University of Wisconsin Cancer Center, 01/23/2018

Ehab Atallah, MD, The Divide between Clinical Research and Clinical Practice, Fifth annual clinical research symposium, 10/05/2018

Ehab Atallah, MD, AML: An update, Seventh annual advances in hematology and oncology fall symposium, 11/10/2018

Ehab Atallah, MD, Hematologic Malignancies,, OncLive® State of the Science Summit, Milwaukee, WI, 04/23/2019

Ehab Atallah, MD, Updates on AML, grand rounds, St. Vincent Hospital, Green Bay, WI, 09/11/2020

Ehab Atallah, MD, Leukemia for primary care, Watertown clinic, 10/01/2020

Ehab Atallah, MD, Why is there no standard of care in relapsed/refractory AML?, Acute Leukemia Forum 2020, 10/15/2020

Ehab Atallah, MD, Leukemia/Lymphoma, Onclive Institutional Perspectives in Cancer, 05/20/2021

Ehab Atallah, MD, Cancer Prevention & Outcomes Research Program. Curing CML: Where do we go from here?, MCWS Cancer Center Seminar Series, 09/24/2021

Ehab Atallah, MD, Updates on Leukemia, St. Agnes Hospital, 10/12/2022

Ehab Atallah, MD, Progress in Myeloid malignancies: Case presentations, 11th Annual Advances in Hematology and Oncology Fall Symposium, 10/29/2022

Ehab Atallah, MD, Leukemia, Lymphoma Society: National Blood Cancer Conference, 09/09/2023

Ehab Atallah, MD, OncLive® State of the Science Summit, 09/20/2023

Ehab Atallah, MD, Myelodysplastic Syndrome, Oncology Lecture Series, Bellin Health, 11/29/2023

**Local**

Ehab Atallah, MD, Hematology Update Meeting, Milwaukee, WI, 2009 - 2011

Ehab Atallah, MD, Leukemia: Have we made progress, Grand Rounds, FMLH, The Department of Medicine, 03/04/2011

Ehab Atallah, MD, First Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/24/2012

Ehab Atallah, MD, Second Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/09/2013

Ehab Atallah, MD, Leukemia for primary care, Columbia St. Mary's grand rounds, Milwaukee, WI, 09/24/2013

Ehab Atallah, MD, Third Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/08/2014

Ehab Atallah, MD, Hematology and Leukemia, Family nurse practitioner doctorate class, University of Wisconsin-Milwaukee College of Nursing Hematology and Leukemia, 09/02/2015

Ehab Atallah, MD, Leukemia for the FISHers and Karyotypers, MCW cytogenetics lab, 04/03/2017

Ehab Atallah, MD, CML, MCW Cancer center board of directors meeting, MCW Cancer center, 12/13/2017

Ehab Atallah, MD, To transplant or not to transplant: That is the question, BMT education, MCW, 05/10/2018

Ehab Atallah, MD, CML: An Update, Eighth Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/09/2019

Ehab Atallah, MD, Intensive vs. Less Intensive therapy in AML, Ninth Annual Controversies in Hematological Malignancies, Milwaukee, WI, 03/01/2020

Ehab Atallah, MD, Frankly speaking about leukemia, Gildas club, 10/13/2021

Ehab Atallah, MD, CML Updates, Pediatric Tumor Board, Children’s Hospital of Wisconsin

**PEER REVIEWED WORKSHOPS/PRESENTATIONS:**

**National**

Atallah E , Kantarjian H , O'Brien S , Jones D , Borthakur G Nicaise C , Cortes J. Dasatinib, (SPRYCEL ®) is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase, American Society of Clinical Oncology Meeting, Chicago, 06/2007

Verstovsek S, Atallah E, Thomas D, Cortes J, Ravandi-Kashani F, Nicaise C,Sams I, Giles F, Kantarjian H. Dasatinib, Therapy for Patients with Philadelphia negative Myeloproliferative Disorders Including Systemic Mastocytosis, ASCO, 2007

Olatoyosi Odenike, Emily Curran, Neil Iyengar, Leslie Popplewell, Mark Kirschbaum, Harry P Erba, Margaret Green, Xavier Poiré, Pamela Ihonor, Ernesto Diaz-Flores, Kevin Shannon, Ehab Atallah, James L Wade, III, Maria Perdekamp, Sreenivasa Nattam, Sachdev P. Thomas, Scott E. Smith, L. Austin Doyle, Elizabeth Shima Rich, Richard A. Larson, and Wendy Stock, Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML), Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2081

Mark Kirschbaum, Ivana Gojo, Stuart L. Goldberg, Lisa Kujawski, Ehab Atallah, Peter Marks, Donna Di

Gravio, Lisa Pyle, Syed Rizvi, and Jean-Pierre J Issa, Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study, Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2089

T.A. Giever, K.M. Adwan, Y. Cheng, E.L. Atallah, Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy, J Clin Oncol 28:15s, 2010 (suppl;abstr 9033)

Atallah E, Durand J, Kantarjian H, Jabbour E, O'Brien S, Rios M, Cortes J., Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy, Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2146

Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S, Kornblau S, Cortes J., Impact of Imatinib Mesylate Dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML), Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 1035

Atallah E, Verstovsek S., Clinical Features and Prognosis of Patients with Myelodysplastic/Myeloproliferative Syndrome-Unclassified (MDS/MPD-U): Refractory Anemia with Ringed Sideroblasts with Thrombocytosis (RA-RST) is a Favo, Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2612

Kirschbaum M, Gojo I, Goldberg S, Kujawski L, Atallah E, Marks P, Garcia-Vargas J, Rizvi S, Di Gravio D, Ahern J and Issa JP, Phase I Study of Vorinostat in Combination with Decitabine in Patients with Relapsed or Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome, Blood (ASH Annual Meeting Abstracts), Dec 2008; 112: 3651

**MCW TEACHING ACTIVITIES:**

**Medical Student Education**

2008 - Present Clinical preceptorship: Ambulatory immersion rotation for medical students
2010 - 2012 Instructor in the “General Principles” Module of the M1 Curriculum, “Neoplasia and Carcinogenesis”
2011 Preceptor for CER History & Physical for M2 students
2012 Instructor in the “General Principles” Module of the M2 Curriculum, “Neoplasia and Carcinogenesis”
2013 - 2015 Clinical Apprenticeship Preceptor
2014 - 2021 Instructor in the “Heme/lymph” Module of the M2 Discovery Curriculum
2015 Molecules to cells case based discussions

**Resident and Fellow Education**

03/17/2009 Fellows Core curriculum lecture CLL
03/24/2009 Fellows Core Curriculum lecture CML
05/06/2009 Resident Core curriculum lecture: Chronic Leukemia and myeloproliferative neoplasms
10/19/2010 Core Education Session – CLL
01/25/2011 Core Education Session - CML
Fellows Clinical preceptorship -Jenny Petkova, Leena Varkey and Sunita Sukumaran
Resident Clinical preceptorship: Ambulatory clinical rotations for residents

**Nursing Student Education**

03/2009 Leukemia for Nurses
01/08/2013 1/8/2013 Leukemia for Nurses. What you need to know
11/2014 Therapy related AML
12/06/2017 Therapy related AML

**EXTRAMURAL TEACHING:**

**Community/Lay Public**

Chronic Lymphocytic Leukemia Support Group in Wisconsin: Sponsor
Milwaukee CML connection. National CML society: Sponsor

**MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:**

**Medical Students**

08/2009 Vernon M, Research Advisor, Medical College of Wisconsin, Resolution of rheumatoid arthritis symptoms with imatinib mesylate. Journal of clinical Rheumatology. 15(5):267

**Clinical/Research Fellows**

08/2014 Randhawa, J., Research mentorship and protocol writing, Medical College of Wisconsin, Myelodysplastic syndrome. Hospital Physician. Hematology Board Review Manual. Volume 9, Part 3

10/30/2014 - 11/01/2014 Peswani N., Research mentorship and protocol writing, Medical College of Wisconsin, D-Dimer Kinetics, Chemotherapy And The Risk Of Bleeding In Patients With Acute Promyelocytic Leukemia. Congress on Controversies in Thrombosis and Hemostasis (CiTH). Berlin, Germany

Peswani N., Research mentorship and protocol writing, Medical College of Wisconsin, D-Dimer Kinetics, Chemotherapy and Risk of Bleeding in Acute Promyelocytic Leukemia (Blood 2014 124:1490)

Badar T, Research mentorship and protocol writing, Medical College of Wisconsin, Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2. doi: 10.1016/j.clml.2020.03.004. Epub 2020 Mar 19.PMID: 32291234

Guru, M, Research mentorship and protocol writing, Medical College of Wisconsin, A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and secondary Acute Myeloid Leukemia (AML)

Badar T, Research mentorship and protocol writing, Medical College of Wisconsin, Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 May 26;4(10):2308-2316. doi: 10.1182/bloodadvances.2019001381.PMID: 32453836

Randhawa, J, Research mentorship and protocol writing, Medical College of Wisconsin, Phase I study combining POMP (Prednisone, vincristine, methotrexate and 6-mercaptopurine) maintenance therapy with and oral proteasome inhibitor MLN9708.

Badar T, Research mentorship and protocol writing, Medical College of Wisconsin, Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 Apr 6. doi: 10.1038/s41409-021-01279-w. Epub ahead of print. PMID: 33824440.

Badar T, Research mentorship and protocol writing, Medical College of Wisconsin, Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2020 Dec 1. doi: 10.1002/cncr.33340. Epub ahead of print. PMID: 33259056.

Guru, M., Research mentorship and protocol writing, Medical College of Wisconsin, Incidence and Outcomes of T-Cell Acute Lymphoblastic Leukemia (T-ALL) in United States. Blood 2017 130:2575

Guru, M, Research mentorship and protocol writing, Medical College of Wisconsin, Recent Trends in the Incidence and Outcomes of Acute Promyelocytic Leukemia in United States. Blood 2017 130:2578;

**Residents**

2010 Angel, J. R., Research Advisor, Medical College of Wisconsin, Recurrent deep vein thrombosis and pulmonary embolism in a young man with klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298>C. Blood Coagulation & Fibrinolysis: An international Journal in Haemostatsis and Thrombosis, 21(4), 372-375

Bilgi N., Research Advisor, Medical College of Wisconsin, Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. 2010 May;44(5):926-8.

Jasleen K., Research Advisor, Medical College of Wisconsin, Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4157

**Faculty**

Guru M, Research Mentoring and protocol writing, Medical College of Wisconsin, SH CRTI project. Assessment of the role of frailty and comorbid conditions on the outcomes of adult patients with acute lymphoblastic leukemia. Role: Institutional mentor

Guru M (Co-PI), Research Mentoring and protocol writing, Medical College of Wisconsin, Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE)

Narra RK, Research Mentoring and protocol writing, Medical College of Wisconsin, Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017 Sep 25. PubMed PMID: 28944397.

Abedin S, Research Mentoring and protocol writing, Medical College of Wisconsin, Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Abedin S., Research Mentoring and protocol writing, Medical College of Wisconsin, Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

**EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:**

**Residents**

T.A. Giever, Research Advisor, Medical College of Wisconsin, Milwaukee, WI: Clement J. Zablocki V.A. Medical Center, Milwaukee, WI, Comparison of venous thromboemboli (VTE) incidence in cancer patients who are on statin therapy versus those not on statin therapy. J Clin Oncol 28:15s, 2010 (suppl;abstr 9033)

## BIBLIOGRAPHY

**Refereed Journal Publications/Original Papers**


1. **Atallah E**, Talpaz M, O'Brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic Myelogenous Leukemia In T Cell Lymphoid Blastic Phase Achieving Durable Complete Cytogenetic And Molecular Remission With Imatinib Mesylate (STI571; Gleevec) Therapy. Cancer 2002; 94(11):2996-2999.
2. **Atallah E**, Durand J, Kantarjian H, Cortes J. Congestive Heart Failure is a Rare Event in Patients Receiving Imatinib Therapy. Blood. 2007 Aug 15;110(4):1233-7
3. **Atallah E**, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of Baseline Toxicity Expectations with Standard Frontline Chemotherapy in Acute Myelogenous Leukemia. Blood. 2007 Nov 15;110(10):3547-51.
4. Nand, J, Bryke C, Divgi A, Kroft S, Bredeson C, **Atallah E**. Myeloproliferative Disorder with Eosinophilia and ETV6-ABL Gene Rearrangement: Efficacy of Second Generation Tyrosine Kinase Inhibitors. Leukemia Research. 2009 Aug;33(8):1144-6. Epub 2009 Apr 25.
5. Bilgi N, Bell K, Ananthakrishnan AN, **Atallah E**. Ann Pharmacother. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. 2010 May;44(5):926-8. Epub 2010 Mar 23.
6. Olteanu H, Schur BC, Bredeson C, **Atallah E**, Kroft SH.Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. Leuk Lymphoma. 2010 Mar;51
7. Atallah, E., Abrams, J., Ayash, L., Bentley, G., Abidi, M., Ratanatharathorn, V., et al. (2010). Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. American Journal of Hematology, 85(8): 579-83.
8. Angel, J. R., Parker, S., Sells, R.E., & Atallah, E. (2010). Recurrent deep vein thrombosis and pulmonary embolism in a young man with klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298>C. Blood Coagulation & Fibrinolysis: An international Journal in Haemostatsis and Thrombosis, 21(4), 372-375.
9. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, **Atallah E**, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. Am J Hematol. 2017 Sep;92(9):E563-E565.
10. Khoury HJ, Williams LA, **Atallah E**, Hehlmann R. Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. Am Soc Clin Oncol Educ Book. 2017;37:468-479.
11. Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M,

Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, **Atallah E**, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20;35(24):2745-2753. PMCID: PMC5562170

12. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, **Atallah E**, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.
13. Talpaz M, Saglio G, **Atallah E**, Rousselot P. Dasatinib dose management for the treatment of chronic myeloid leukemia. Cancer. 2018 Apr 15;124(8):1660-1672. PMCID: PMC5901015
14. **Atallah E**, Ritchie E. Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? Expert Opin Pharmacother. 2018 Feb;19(2):79-81.
15. **Atallah E**, Schiffer CA. Granulocyte transfusion. Curr Opin Hematol. 2006 Jan;13(1):45-9.
16. Narra RK, Flynn KE, **Atallah E**. Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. Curr Hematol Malig Rep. 2017 Oct;12(5):415-423. PMCID: PMC6045428
17. Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, **Atallah E**, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr;17(4):496-508.
18. Flynn KE, **Atallah E**. Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016 Apr;11(2):80-5. PMCID: PMC4860261
19. **Atallah E**, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 Apr 02;18(1):359. PMCID: PMC5879565
20. Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, **Atallah E**, Hari P, Carlson K. Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. Acta Haematol. 2018;139(3):171-175. PMCID: PMC6388419
21. Guru Murthy GS, Hamadani M, Dhakal B, Hari P, **Atallah E**. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018 Aug;71:95-99.
22. Voshtina E, Huang H, Raj R, **Atallah E**. Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. Case Rep Hematol. 2018;2018:6514604. PMCID: PMC6092972
23. **Atallah E**, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer. 2002 Jun 01;94(11):2996-9.
24. **Atallah E**, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol. 2005 May;6(3):185-93.
25. **Atallah E**, Schiffer CA. Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? Leuk Res. 2007 May;31(5):720-1.
26. **Atallah E**, Kantarjian H, Garcia-Manero G. The role of decitabine in the treatment of myelodysplastic syndromes. Expert Opin Pharmacother. 2007 Jan;8(1):65-73.
27. **Atallah E**, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med. 2007 Jan;13(1):14; author reply 15-6.
28. **Atallah E**, Cortes J. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. Curr Opin Hematol. 2007 Mar;14(2):138-44.
29. **Atallah E**, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S105-12.
30. **Atallah E**, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007 Aug 15;110(4):1233-7.
31. **Atallah E**, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ,

Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007 Nov 15;110(10):3547-51.
32. **Atallah E**, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin Adv Hematol Oncol. 2007 Jul;5(7):544-52.
33. **Atallah E**, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia. 2008 Jun;22(6):1295-8.
34. **Atallah E**, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest. 2008 Mar;26(2):208-16.
35. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, **Atallah E**. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res. 2009 Aug;33(8):1144-6.
36. **Atallah E**, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther. 2009 May;9(5):663-70. PMCID: PMC5176249
37. O'Dwyer M, **Atallah E**. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol. 2009 Apr;46(2 Suppl 3):S16-21.
38. Vernon MR, Pearson L, **Atallah E**. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol. 2009 Aug;15(5):267.
39. Olteanu H, Schur BC, Bredeson C, **Atallah E**, Kroft SH. Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. Leuk Lymphoma. 2010 Mar;51(3):481-7.
40. Bilgi N, Bell K, Ananthakrishnan AN, **Atallah E**. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother. 2010 May;44(5):926-8.
41. Angel JR, Parker S, Sells RE, **Atallah E**. Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. Blood Coagul Fibrinolysis. 2010 Jun;21(4):372-5.
42. **Atallah E**, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J. Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. Am J Hematol. 2010 Aug;85(8):579-83. PMCID: PMC3800118
43. **Atallah E**. Nilotinib cardiac toxicity: should we still be concerned? Leuk Res. 2011 May;35(5):577-8.
44. Kim J, Haddad RY, **Atallah E**. Myeloproliferative neoplasms. Dis Mon. 2012 Apr;58(4):177-94.
45. Torgerson SR, Haddad RY, **Atallah E**. Chronic myelogenous leukemia for primary care physicians. Dis Mon. 2012 Apr;58(4):168-76.
46. Randhawa J, Ostojic A, Vrhovac R, **Atallah E**, Verstovsek S. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol. 2012 Aug 01;5:43. PMCID: PMC3464878
47. Randhawa J, Wong S, **Atallah E**, Olasz E. Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. Int J Dermatol. 2014 Jan;53(1):e13-4.
48. **Atallah E**, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs. 2012 Dec;17(4):555-70. PMCID: PMC5009610
49. Saber W, Cutler CS, Nakamura R, Zhang MJ, **Atallah E**, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013 Sep 12;122(11):1974-82. PMCID: PMC3772501
50. Kremyanskaya M, **Atallah EL**, Hoffman R, Mascarenhas JO. Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park). 2013 Jul;27(7):706-14.
51. Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, **Atallah EL**, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15;20(2):490-8. PMCID: PMC4310865
52. Verstovsek S, Gotlib J, Gupta V, **Atallah E**, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA. Management of cytopenias in patients with myelofibrosis

treated with ruxolitinib and effect of dose modifications on efficacy outcomes. Onco Targets Ther. 2013;7:13-21. PMCID: PMC3869911
53. **Atallah E**, Bylow K, Troy J, Saber W. Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). Curr Hematol Malig Rep. 2014 Mar;9(1):57-65. PMCID: PMC4031643
54. Kantarjian HM, Lioure B, Kim SK, **Atallah E**, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H. A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):139-45. PMCID: PMC5557033
55. Hanif A, Hari PN, **Atallah E**, Carlson KS, Pasquini MC, Michaelis LC. Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. Bone Marrow Transplant. 2016 Apr;51(4):617-8.
56. Verstovsek S, **Atallah E**, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J. Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. Leukemia. 2016 Jun;30(6):1413-5. PMCID: PMC4895165
57. Cornell RF, Zhong X, Arce-Lara C, **Atallah E**, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. Bone Marrow Transplant. 2015 Jul;50(7):914-7.
58. Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, **Atallah E**, Burn T, Sun W, Sandor V, Gotlib J. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):214-221.e1. PMCID: PMC4418454
59. Kataria A, Cohen E, Saad E, **Atallah E**, Bresnahan B. Large granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. Transplant Proc. 2014 Dec;46(10):3278-81.
60. Yan M, Geyer H, Mesa R, **Atallah E**, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V. Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):e1-5. PMCID: PMC4361182
61. Troy JD, **Atallah E**, Geyer JT, Saber W. Myelodysplastic syndromes in the United States: an update for clinicians. Ann Med. 2014 Aug;46(5):283-9.
62. Guru Murthy GS, Pemmaraju N, **Atallah E**. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leuk Res. 2018 Oct;73:21-23.
63. Guru Murthy GS, Pondaiah SK, Abedin S, **Atallah E**. Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. Leuk Lymphoma. 2019 May;60(5):1171-1178.
64. Raj RV, Abedin SM, **Atallah E**. Incorporating newer agents in the treatment of acute myeloid leukemia. Leuk Res. 2018 Nov;74:113-120.
65. Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, **Atallah EL**. Implementation and evaluation of high-dose methotrexate administration guidelines. J Oncol Pharm Pract. 2019 Oct;25(7):1675-1681.
66. Guru Murthy GS, **Atallah E**. Treatment-Free Remission in CML: the US Perspective. Curr Hematol Malig Rep. 2019 Feb;14(1):56-61.
67. Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, **Atallah E**. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019 Feb 26;3(4):508-518. PMCID: PMC6391673
68. Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, **Atallah EL**. Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Leuk Lymphoma. 2019 Jun;60(6):1476-1484.
69. Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, **Atallah E**. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Oncologist. 2019 Sep;24(9):1253-1258. PMCID: PMC6738285
70. Kota V, **Atallah E**. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):480-487.
71. Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, **Atallah E**. Patients' perspectives on the definition of cure in chronic myeloid leukemia.

Leuk Res. 2019 May;80:40-42.
72. **Atallah E**, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2020 Apr 01;6(4):486-493. PMCID: PMC6990739
73. Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, **Atallah E**. Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. J Natl Compr Canc Netw. 2020 Feb;18(2):169-175.
74. Jain N, Stock W, Zeidan A, **Atallah E**, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 Feb 11;4(3):449-457. PMCID: PMC7013258
75. Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, **Atallah E**. In Reply. Oncologist. 2020 Apr;25(4):e744-e745. PMCID: PMC7160403
76. Goldberg AD, **Atallah E**, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study Leukemia Research. August 2020;95.
77. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, **Atallah E**, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study Leukemia Research. July 2020;94.
78. Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, **Atallah E**. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk. 2020 Aug;20(8):556-560.e2.
79. Goldberg AD, **Atallah E**, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 Aug;95:106385.
80. Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, **Atallah E**. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 May 26;4(10):2308-2316. PMCID: PMC7252553
81. George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, **Atallah E**, Baumann-Kreuziger L. Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. Leuk Res. 2020 Jul;94:106368.
82. Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, **Atallah E**. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 Apr 01;127(7):1039-1048.
83. **Atallah E**, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01;7(1):42-50. PMCID: PMC7662490
84. **Atallah E**, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica. 2020 Dec 01;105(12):2738-2745. PMCID: PMC7716356
85. Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, **Atallah EL**, Guru Murthy GS. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual

disease in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma. 2021 Jan;62(1):158-166.
86. **Atallah EL**, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V. Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. Leuk Lymphoma. 2021 Jul;62(7):1730-1739.
87. Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, **Atallah E**. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data Bone Marrow Transplantation. 2021.
88. **Atallah EL**. Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making Best Practice and Research: Clinical Haematology. 2021.
89. Schoenbeck KL, **Atallah E**, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. PMCID: PMC8755495
90. Badar T, **Atallah E**. Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? Expert Opin Investig Drugs. 2021 Jun;30(6):665-673.
91. Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, **Atallah E**. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 Aug;56(8):1998-2004.
92. **Atallah EL**. Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. Best Pract Res Clin Haematol. 2021 Mar;34(1):101240.
93. **Atallah E**, Sweet K. Treatment-Free Remission: the New Goal in CML Therapy. Curr Hematol Malig Rep. 2021 Oct;16(5):433-439. PMCID: PMC8495665
94. **Atallah E**, Garcia-Manero G. Epigenetic Drugs: DNA Demethylating Agents Epigenetics in Biology and Medicine. 1 January 2008:27-48.
95. Badar T, **Atallah E**, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 Jul;97(7):E232-E235.
96. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, **Atallah E**, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Récher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu Q, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 Jun 09;139(23):3366-3375. PMCID: PMC9197557
97. Corrao K, Rezwan S, **Atallah E**, Michaelis LC, Runaas L, Harrington AM, Abedin S. Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome. Leuk Res Rep. 2022;17:100329. PMCID: PMC9150024
98. Guru Murthy GS, **Atallah E**. Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults: Progress and Challenges. JCO Oncol Pract. 2022 Jul;18(7):489-490.
99. Murthy GSG, **Atallah E**. Targeting TIM-3 as a new strategy in immunotherapy: focus on sabatolimab Drugs of the Future. November 2021;46(11):901-905.
100. Sasaki K, Mauro MJ, Levy MY, **Atallah EL**, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE. CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S299.
101. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States. J Health Econ Outcomes Res. 2022;9(2):19-29. PMCID: PMC9352872

102. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A. Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective. J Health Econ Outcomes Res. 2022;9(2):30-36. PMCID: PMC9353133
103. Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, **Atallah E**. A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. J Cancer Prev. 2022 Jun 30;27(2):129-138. PMCID: PMC9271408
104. **Atallah E**. Low-intensity induction in acute myeloid leukemia. Always in the patients' best interest? Haematologica. 2023 Apr 01;108(4):949-950. PMCID: PMC10071108
105. Pettit K, Rezazadeh A, **Atallah EL**, Radich J. Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-19.
106. Flynn KE, **Atallah E**, Lin L, Shah NP, Silver RT, Larson RA, Panilla-Ibarz J, Thompson JE, Oehler VG, Radich JP, Kota V, Mauro MJ, Schiffer CA, Cortes J, Weinfurt KP. Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. Haematologica. 2022 Nov 01;107(11):2641-2649. PMCID: PMC9614525
107. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States Journal of Health Economics and Outcomes Research. 2022;9(2):19-29.
108. **Atallah EL**, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A. Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective Journal of Health Economics and Outcomes Research. 2022;9(2):30-36.
109. Badar T, Litzow MR, Shallis RM, Patel A, Saliba AN, Burkart M, Bewersdorf JP, Stahl M, De Camargo Correia GS, Guru Murthy GS, Abaza Y, Duvall A, Bradshaw D, Kota V, Dinner S, Goldberg AD, Palmisiano N, Al Kali A, **Atallah E**. Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 Mar 15;129(6):934-945.
110. Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, **Atallah E**, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Maeda Y, Hosono N, Onozawa M, Kato T, Kim HJ, Hasabou N, Nuthethi R, Tiu R, Levis MJ. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy. Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. PMCID: PMC10189888
111. DeFilipp Z, Ciurea SO, Cutler C, Robin M, Warlick ED, Nakamura R, Brunner AM, Dholaria B, Walker AR, Kröger N, Bejanyan N, **Atallah E**, Tamari R, Solh MM, Percival ME, de Lima M, Scott B, Oran B, Garcia-Manero G, Hamadani M, Carpenter P, DeZern AE. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines. Transplant Cell Ther. 2023 Feb;29(2):71-81.
112. Abedin SM, Badar T, Gauger K, Michaelis LC, Runaas L, Carlson KS, Murthy GG, **Atallah E**. Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory acute myeloid leukemia. Leuk Res. 2022 Dec;123:106984.
113. Advani AS, Moseley A, O'Dwyer KM, Wood BL, Park J, Wieduwilt M, Jeyakumar D, Yaghmour G, **Atallah EL**, Gerds AT, O'Brien SM, Liesveld JL, Othus M, Litzow M, Stone RM, Sharon E, Erba HP. Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia. Blood Adv. 2023 Apr 11;7(7):1279-1285. PMCID: PMC10090098
114. Mikhaeel S, **Atallah E**. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML). Clin Lymphoma Myeloma Leuk. 2023 May;23(5):333-339.
115. Badar T, **Atallah E**, Shallis R, Saliba AN, Patel A, Bewersdorf JP, Grenet J, Stahl M, Duvall A, Burkart M, Palmisiano N, Bradshaw D, Kubiak M, Dinner S, Goldberg AD, Abaza Y, Murthy GSG, Kota V, Litzow MR. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023 Apr;37(4):799-806.
116. Hillis C, Flynn KE, Goldman EH, Moreira-Lucas TS, Visentini J, Dorman S, Ballinger R, Byrnes HF, De

Palma A, Barbier V, Machado L, **Atallah E**. A Survey of Patient Experience in CML: American and Canadian Perspectives. Patient Prefer Adherence. 2023;17:331-347. PMCID: PMC9904222

117. **Atallah E**, Mauro MJ, Hochhaus A, Boquimpani C, Minami Y, Maheshwari VK, Saini L, Corbin R, Réa D. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023 Aug;149(9):6247-6262. PMCID: PMC10356870
118. Rezazadeh A, Deininger M, **Atallah E**. Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia Current Treatment Options in Oncology. 2023.
119. Winn AN, **Atallah E**, Cortes J, Deininger MWN, Kota V, Larson RA, Moore JO, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Shah NP, Thompson JE, Flynn KE. Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid Leukemia. JAMA Netw Open. 2023 Dec 01;6(12):e2347950. PMCID: PMC10728762
120. Held N, **Atallah EL**. Real-world Management of CML: Outcomes and Treatment Patterns. Curr Hematol Malig Rep. 2023 Oct;18(5):167-175.
121. Guru Murthy GS, **Atallah E**. Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia. Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):346-350.
122. Rezazadeh A, Deininger M, **Atallah E**. Proposals for Clinical Trials in Chronic Myelomonocytic Leukemia. Curr Treat Options Oncol. 2023 Aug;24(8):1036-1051.
123. Taylor S, Murthy GSG, Runaas L, Michaelis LC, Carlson K, **Atallah EL**, Abedin SM. Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy. Leuk Res. 2023 Sep;132:107348.
124. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, Othus M, Sun Z, Ries RE, Wang J, Leonti A, Kutny MA, Ostronoff F, Radich JP, Appelbaum FR, Pogosova-Agadjanyan EL, O'Dwyer K, Tallman MS, Litzow M, **Atallah E**, Cooper TM, Aplenc RA, Abdel-Wahab O, Gamis AS, Luger S, Erba H, Levine R, Kolb EA, Stirewalt DL, Meshinchi S, Tarlock K. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv. 2023 Oct 10;7(19):5941-5953. PMCID: PMC10562769
125. **Atallah E**, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ?2 tyrosine kinase inhibitors: a systematic literature review Therapeutic Advances in Hematology. January-December 2023;14.
126. Badar T, Nanaa A, **Atallah E**, Shallis RM, Guilherme SdCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) Blood Cancer Journal. December 2024;14(1).
127. Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, **Atallah E**, Altman JK. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. Am J Hematol. 2024 Apr;99(4):606-614.
128. **Atallah E**, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ?2 tyrosine kinase inhibitors: a systematic literature review. Ther Adv Hematol. 2023;14:20406207221150305. PMCID: PMC10725100
129. **Atallah E**. Eligibility criteria: too big, too small or just right? Haematologica. 2024 Apr 01;109(4):1021. PMCID: PMC10985446
130. Badar T, Nanaa A, **Atallah E**, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 Feb 20;14(1):32. PMCID: PMC10879201
131. Muthiah C, Narra R, **Atallah E**, Juan W, Szabo A, Guru Murthy GS. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry. Leuk Res. 2024 May;140:107496.
132. Litzow MR, Sun Z, Mattison RJ, Paietta EM, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM,

Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, **Atallah EL**, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Luger SM, Mullighan CG, Tallman MS. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25;391(4):320-333. PMCID: PMC11334054

133. Badar T, Nanaa A, **Atallah E**, Shallis RM, Craver EC, Li Z, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, Duvall A, Burkart M, Bradshaw D, Abaza Y, Stahl M, Palmisiano N, Murthy GSG, Zeidan AM, Kota V, Patnaik MM, Litzow MR. Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases. Haematologica. 2024 Nov 01;109(11):3533-3542. PMCID: PMC11532685
134. Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, **Atallah E**, Mauro MJ, Radich JP, Bernardi S, Russo D, Farina M, Mori S, Gambacorti-Passerini C, Civettini I, Lu L, Yeung D, Branford S, Colafigli G, Breccia M, Hogenbirk P, van Rosmalen J, Cornelissen JJ, Westerweel PE. BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis. Am J Hematol. 2024 Aug;99(8):1632-1635.
135. Murthy GSG, Saliba AN, Szabo A, Harrington A, Abedin S, Carlson K, Michaelis L, Runaas L, Baim A, Hinman A, Maldonado-Schmidt S, Venkatachalam A, Flatten KS, Peterson KL, Schneider PA, Litzow M, Kaufmann SH, **Atallah E**. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia. Haematologica. 2024 Sep 01;109(9):2864-2872. PMCID: PMC11367232
136. **Atallah E**, Deininger M. Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations. Drugs. 2025 Jan;85(1):41-50. PMCID: PMC12482972
137. **Atallah EL**, Wei D, Latremouille-Viau D, Rossi C, Damon A, Ferreira G, Guérin A, Jadhav K. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP. Clin Lymphoma Myeloma Leuk. 2025 Mar;25(3):178-187.e2.
138. Badar T, Shahzad M, **Atallah E**, Litzow MR, Kharfan-Dabaja MA. Transplant or no transplant for TP53 mutated AML. Oncotarget. 2024 Oct 01;15:674-676. PMCID: PMC11444334
139. Badar T, Narra R, Mims AS, Heckman MG, Shallis RM, Fahad S, Hunter C, Kota V, Othman TA, Jonas B, Desai S, de Camargo Correia GS, Patel A, DuVall AS, Palmisiano N, Curran E, Omer Z, Advani A, **Atallah E**, Litzow M. Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 Dec;99(12):2388-2391.
140. Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, Gauger K, Desai AG, Chen MM, Li KL, Rotibi M, Syed U, Vusirikala M, Harrington A, **Atallah EL**. Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia. Leukemia. 2025 Apr;39(4):837-843.
141. **Atallah EL**, Mauro MJ, Sasaki K, Levy MY, Koller P, Yang D, Laine D, Sabo J, Gu E, Cortes JE. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncol. 2024;20(38):3065-3075. PMCID: PMC13178178
142. Palmisiano ND, Lee JW, Claxton DF, Paietta EM, Alkhateeb H, Park J, Podoltsev NA, **Atallah EL**, Schaar DG, Dinner SN, Webster JA, Luger SM, Litzow MR. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol. EJHaem. 2024 Oct;5(5):951-956. PMCID: PMC11474352
143. Corrao K, Umpierrez A, Treml A, Szabo A, Michaelis L, Runaas L, Murthy GSG, Abedin S, Carlson K, Kreuziger LB, **Atallah E**. 40 is the new 50: reducing the need for platelet transfusions prior to lumbar puncture in adults with hematologic malignancies. Haematologica. 2025 Aug 01;110(8):1845-1848. PMCID: PMC12358779
144. Zorn KE, Alvarez-Argote J, Meyer AE, Cunningham A, Hintzke M, Giever E, Stelloh C, **Atallah E**, Vassiliou GS, Rao S. An EMT-like signature as a potential driver of myeloid sarcoma. Blood Neoplasia. 2024 Sep;1(3). PMCID: PMC11887653
145. Sarker J, **Atallah EL**, Flynn KE, Winn AN. Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence Leukemia and Lymphoma. 2025.
146. Jamy O, El Kettani M, Shah K, Shallis RM, Diebold K, Coltoff A, Goldberg AD, Patel A, Bewersdorf JP,

Foucar C, Abaza Y, Palmisiano N, DuVall AS, Kota V, Patel SA, Zeidan AM, **Atallah E**, Litzow MR, Badar T. Outcomes of older patients with TP53-mutated myeloid neoplasms. Blood Cancer J. 2025 Oct 07;15(1):160. PMCID: PMC12504439

147. **Atallah E**, Broder MS, Chan O, Flynn KE, Gilreath JA, Hine M, Hunter AM, Mattson HTD, Mauro MJ, Pinilla-Ibarz J, Rein LAM, Stemper E, Tantravahi S, Yang J, Shah NP. Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase. Hematology. 2025 Dec;30(1):2556506.
148. **Atallah EL**, Sadek I, Wei D, Latremouille-Viau D, Rossi C, Damon A, Yang D, Bellefleur R, Guérin A, Jadhav K. Treatment with asciminib after a prior tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia. Leuk Res. 2025 Oct;157:108089.
149. Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, **Atallah EL**, Patel AA, Shallis RM. Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Haematologica. 2026 Jan 01;111(1):158-167. PMCID: PMC12775749
150. Badar T, Foran JM, Bewersdorf JP, Wang YH, Coltoff A, El Kettani M, Shah K, Denis Oliva F, Lin C, Jamy O, Diebold K, Shallis RM, Siddon A, Katkov D, Schoen A, Khan I, Foucar CE, **Atallah E**, Goldberg AD, Patel AA. Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025 Aug;207(2):683-686.
151. **Atallah E**, Lipton JH. Has the time for treatment-free remission in Philadelphia chromosome-positive acute lymphoblastic leukemia arrived? Cancer. 2025 May 15;131(10):e35880.
152. Sarker J, **Atallah EL**, Flynn KE, Winn AN. Tyrosine kinase inhibitor discontinuation and reinitiation patterns in CML patients in the US: real-world evidence. Leuk Lymphoma. 2025 Aug;66(8):1515-1520.

**Books, Chapters, and Reviews**

1. **Atallah E**, Flaherty L. Treatment Of Metastatic Malignant Melanoma. Current Treatment Options in Oncology 2005; 6(3):185-193.
2. **Atallah E**, Garcia-Manero G. New Treatment Strategies in the Treatment of Myelodysplastic Syndrome. Cancer Invest. 2008 Mar;26(2):208-16
3. **Atallah E**, Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clinical Advances in Hematology and Oncology 2007 Jul;5(7):544-52.
4. **Atallah E**, Schiffer CA. Granulocyte Transfusion. Current Opinion in Hematology 2006; 13(1):45-49.
5. **Atallah E**, Garcia-Manero G. The Role of Decitabine in the Treatment of Myelodysplastic Syndromes. Expert Opinion On Pharmacotherapy. Expert Opinion in Pharmacotherapy 2007 Jan;8(1):65-73.
6. **Atallah E**, Cortes J. Optimal Initial Therapy for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. Current Opinion in Hematology 2007 Mar;14(2):138-44.
7. **Atallah E**, Cortes J. Emerging Safety Issues with Abl Kinase Inhibitors. Clinical Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S105-12
8. **Atallah E**. CML. Initial Therapy in Previously Untreated Patients with Chronic Myelogenous Leukemia in Chronic Phase. Clinical Leukemia, Vol. 2, No. 4, 248-251, 2008
9. **Atallah E**, Verstovsek S. The Prospect of JAK2 Inhibitor Therapy in Myeloproliferative Neoplasms. Expert review of anticancer therapy. 2009 May;9(5):663-70.
10. **Atallah E**, O'Dwyer. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Seminars in Hematology April 2009 (Vol. 46, Pages S16-S21)
11. **Atallah E**, Garcia-Manero G. Hypomethylating agents Chapter in "Epigenetics in Biology and Medicine". Editor Dr. Manel Esteller

**Editorials, Letters To Editor, Other**

1. **Atallah E**, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S.JAK-2 mutation in patients with myelodysplastic/myeloproliferative disorders unclassifiable and refractory anemia with ringed sideroblasts and thrombocytosis (RARS-T) is associated with good prognosis. Leukemia. 2008 Jun;22(6):1295-8.
2. **Atallah E**, Kantarjian H, Cortes J. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nature Medicine 2007 Jan;13(1):14.
3. **Atallah E**, Schiffer CA. Agent Orange, Prostate Cancer Irradiation And Acute Promyelocyic Leukemia

(APL): Is There A Link? Leukemia Research 2006.
4. Vernon M, Pearson L, **Atallah E**. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. Journal of clinical Rheumatology. 15(5):267, August 2009
5. **Atallah E**. Nilotinib cardiac toxicity: Should we still be concerned? Leuk Res. 2011 Feb 16

**Non-Refereed Journal Publications/Original Papers**

1. **Atallah E**, O'Dwyer. Practical considerations for the management of patients in the tyrosine kinase inhibitor era. Semin Hematol. 2009 Apr;46(2 Suppl 3):S16-21

**Abstracts**

1. **Atallah E**, Uberti J, Ayash L, Bentley G, VanDahm J, Ratanatharathorn V. Fifteen-Year Follow up of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes Using Busulfan-Based Regimens. ASH Annual Meeting Abstracts 2005; 106(11):5461.
2. **Atallah E**, Kantarjian H, De Lima M, Borthakur G, Wierda W, Champlin R, Cortes J. The Role of Dasatinib in Patients with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) Relapsing after Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 4520.
3. **Atallah E**, O'Brien S, Kaled S, Lynn A, Cortes J, Kantarjian H, Thomas D
4. Traumatic Lumbar Puncture (TLP) Is Not Associated with Worse Outcome in Adults with Acute Lymphocytic Leukemia (ALL) or Burkitt-Type Leukemia/Lymphoma (BLL) Receiving Hyper-CVAD Regimens. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4346.
5. **Atallah E**, O'Brien S, Kaled S, Lynn A, Cortes J, Kantarjian H, Thomas D
6. Safety of Lumbar Puncture (LP) and Instillation of Intrathecal (IT) Chemotherapy during Thrombocytopenia in Adults with Acute Lymphocytic Leukemia (ALL).
7. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 4347.
8. Jasleen K Randhawa, MD, Christopher Bredeson, MD2, Timothy S. Fenske, MD2, Ayman Saad, MD3, Jeanne Palmer, MD4, Parameswaran N Hari, MD5, Horatiu Olteanu*,6 and Ehab Atallah, MD2. Hypomethylating Agent Therapy for Acute Myelogenous Leukemia (AML) Can Induce Sustained Responses with Low Induction Mortality. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 4157.

**Peer Reviewed Educational Products**

1. **Atallah E**, Tam C, O'Brien S. CLL the cutting edge. CME educational activity